# Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)

> **NCT01416636** · PHASE3 · COMPLETED · sponsor: **SciPharm SàRL** · enrollment: 105 (actual)

## Conditions studied

- Non-operable Chronic Thromboembolic Pulmonary Hypertension

## Interventions

- **DRUG:** Treprostinil sodium

## Key facts

- **NCT ID:** NCT01416636
- **Lead sponsor:** SciPharm SàRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2016-11
- **Final completion:** 2021-04
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416636, "Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01416636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*